Results 51 to 60 of about 2,781,261 (274)

In silico and in vitro studies confirm Ondansetron as a novel acetylcholinesterase and butyrylcholinesterase inhibitor

Scientific Reports, 2023
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that is growing rapidly among the elderly population around the world.
Asma Gholami, Dariush Minai-Tehrani, Leif A. Eriksson   +2 more
doaj   +1 more source

Chemical Composition, Antioxidant, Antimicrobial, Antidiabetic, and Butyrylcholinesterase Inhibitory Activities in Vitro of the Essential Oil and Crude Extracts of the Aerial Parts of Thymus ciliatus

Chemistry &Biodiversity, EarlyView.
ABSTRACT This study explores the potential of Thymus ciliatus as a natural source of bioactive compounds by investigating its chemical composition and in vitro biological activities, including antioxidant, antimicrobial, antidiabetic, and anti‐Alzheimer properties.
Nadia Djermane, Mostapha Brahmi, Djallal Eddine Adli, Micaela Gliozzi, Vincenzo Musolino, Rebbas Khellaf, Ramazan Erenler, Rabah Arhab, Stefania Garzoli   +8 more
wiley   +1 more source

Synthesis, pharmacology and molecular docking on multifunctional tacrine-ferulic acid hybrids as cholinesterase inhibitors against Alzheimer’s disease

Journal of Enzyme Inhibition and Medicinal Chemistry, 2018
The cholinergic hypothesis has long been a “polar star” in drug discovery for Alzheimer’s disease (AD), resulting in many small molecules and biological drug candidates. Most of the drugs marketed for AD are cholinergic.
Jie Zhu, Hongyu Yang, Yao Chen, Hongzhi Lin, Qi Li, J. Mo, Yaoyao Bian, Yuqiong Pei, Haopeng Sun   +8 more
semanticscholar   +1 more source

The Phenolic Content and Bioactivity Assessment of Rubus sanctus Schreber Species with Potential for Food and Ethnopharmacological Uses

Chemistry &Biodiversity, EarlyView.
ABSTRACT In this study, the phytochemical content and various biological activities of Rubus sanctus Schreber species, widely distributed in Turkiye and used in folk medicine, were determined. The ethanol extracts of the root and aerial parts of the species were prepared and their bioactive phytochemical composition was identified by liquid ...
Ismail Yener
wiley   +1 more source

Benzophenone Semicarbazones as Potential alpha-glucosidase and Prolyl Endopeptidase Inhibitor: In-vitro free radical scavenging, enzyme inhibition, mechanistic, and molecular docking studies [PDF]

arXiv, 2023
$\alpha$-glucosidase and prolylendopeptidase has altered expression and activity patterns in neurological disease, type 2diabetes respectively and several cancers. Here we screened a series 1-29 benzophenone semicarbazone derivatives for in vitro free radical scavenging, alpha-glucosidase and prolylendopeptidase inhibition activities. Seven derivatives
arxiv  

Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis [PDF]

World Journal of Hepatology, 6(10):759-765, 2014, 2014
AIM: To investigate the predictability of interleukin-28B single nucleotide polymorphism rs12979860 with respect to sustained virological response (SVR) in chronically hepatitis C virus (HCV) genotype-1 patients treated with a protease-inhibitor and pegylated interferon-$\alpha$ (Peg-INF-$\alpha$) based triple-therapy.
arxiv   +1 more source

Synthesis and Biological Evaluation of New Cholinesterase Inhibitors for Alzheimer’s Disease

Molecules, 2018
Alzheimer’s disease (AD) is a neurodegenerative disorder mostly influencing the elderly, and causes death due to dementia. The main pathogenic feature connected with the progression of this multifactorial disease is the weakening of the cholinergic ...
Weiam A. Hussein, B. Sağlık, Serkan Levent, Büşra Korkut, Sinem Ilgın, Y. Özkay, Z. Kaplancıklı   +6 more
semanticscholar   +1 more source

Translational Medicine in Alzheimer's Disease: The Journey of Donanemab From Discovery to Clinical Application

Chronic Diseases and Translational Medicine, EarlyView.
Donanemab, approved by the U.S. FDA in July 2024, targets amyloid plaques in the brain to treat Alzheimer's disease in patients with mild cognitive impairment or mild dementia. ABSTRACT Substantial research has been conducted to identify an efficient treatment for Alzheimer's disease (AD).
Nandhini Jayaprakash, Karthikeyan Elumalai   +1 more
wiley   +1 more source

Bioequivalence of a Donepezil/Memantine 10/20 mg Fixed‐Dose Combination Versus Single‐Component Tablets in Healthy Korean Males

Clinical Pharmacology in Drug Development, EarlyView.
Abstract A fixed‐dose combination (FDC) tablet formulation of donepezil/memantine (10/20 mg) was developed to improve medication compliance in patients with Alzheimer's disease (AD). This study compared the pharmacokinetic (PK) characteristics and safety profiles of an FDC formulation (donepezil/memantine [10/20 mg]) and single components (SCs) of ...
Minkyu Choi, Byung Hak Jin, Do Hoon Keum, Kyoung Hoon Mo, Min Soo Park, Juhwan Lee, Sungjin Park, Choon Ok Kim   +7 more
wiley   +1 more source

Synthesis and biological evaluation of lycorine derivatives as dual inhibitors of human acetylcholinesterase and butyrylcholinesterase

Chemistry Central Journal, 2012
Background Alzheimer’s disease (AD) is a neurologically degenerative disorder that affects more than 20 million people worldwide. The selective butyrylcholinesterase (BChE) inhibitors and bivalent cholinesterase (ChE) inhibitors represent new treatments ...
Wang Yue-Hu, Wan Qin-Li, Gu Cheng-Ding, Luo Huai-Rong, Long Chun-Lin   +4 more
doaj   +1 more source